Modified stent graft device for aortic arch surgery in aortic aneurysm or dissection
Tests a modified graft device's safety during aortic arch replacement in adults.
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Registry title
- A Novel Wire-Reinforced Fenestration of a Hybrid Frozen Elephant Trunk Device for Supra-Aortic Branch Vessel Stenting During Aortic Arch Replacement
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 31 Dec 2032
- Type of study
- Interventional
- Treatments tested
- Modified Supra-Aortic Frozen Elephant Trunk (SA-FET) Device
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who need surgery to replace the aortic arch, the curved part of the main artery from the heart. They will receive a modified hybrid frozen elephant trunk device (Thoraflex Hybrid) that allows stents in the arch's branch arteries.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Disease of the aorta in the chest that needs repair or replacement of several damaged segments. This includes an aneurysm, a pseudoaneurysm or a penetrating aortic ulcer at risk of bursting or complications, an acute aortic dissection (a tear) needing urgent repair, or a congenital (present from birth) aortic disease needing repair. Expected to live more than two years after repair.
Main reasons for not taking part
- Not fit enough for open surgery that needs the blood circulation stopped
- In a coma or with severe, lasting lack of blood flow to the brain
- Can be treated with an FDA-approved device on the market, or can join a study sponsored by a device maker
- Active infection in the body, or a bleeding problem that cannot be corrected
- Pregnant
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 18 years or older
- Willing and able to give written informed consent, or the patient's legally authorized representative has given written informed consent
- Expected life expectancy of more than two years after repair
- Aortic pathology requiring repair or replacement of multiple damaged or diseased segments of the thoracic aorta, with at least one of the following: (a) thoracic aortic aneurysm at increased risk for rupture or complications; (b) acute aortic dissection requiring urgent repair; (c) aortic pseudoaneurysm at risk for rupture or complications; (d) penetrating aortic ulcer (PAU) at risk for rupture or complications; (e) congenital aortic disease requiring repair
Who cannot take part
- Unfit for open surgical repair involving circulatory arrest
- Currently participating in an investigational drug or another device study within 6 months before the date of implant, or has not reached the primary endpoint of that study
- Eligible for treatment with a U.S. Food and Drug Administration (FDA)-approved marketed device
- Active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure
- Uncorrectable bleeding anomaly
- Other medical, social, or psychological conditions that, in the opinion of the investigator, preclude appropriate consent or adherence to the follow-up examinations required by the protocol
- Comatose or suffering from irreversible severe brain malperfusion
- Known sensitivity to components of the devices
- Willing and eligible for enrollment in a manufacturer-sponsored clinical study at any institution
- Willing and eligible to participate in a study with a manufacturer-made device at any institution
- Pregnant
Where in United States
- University of Maryland Medical CenterBaltimore, United StatesContact: Kaitlyn Masih, BSNNot yet recruiting
About the trial
What the trial wants to find out
The goal of this prospective, non-randomized trial is to determine the safety and technical success of a novel modification to a U.S. Food and Drug Administration (FDA)-approved hybrid frozen elephant trunk (FET) device (Thoraflex Hybrid, Terumo Aortic). The modification is intended to enable supra-aortic vessel stenting in patients undergoing aortic arch replacement for aortic aneurysm or dissection.
The group in the trial
- Supra-aortic frozen elephant trunk (SA-FET)Treatment being tested
Patients undergoing aortic replacement using the novel modified SA-FET technique.
Treatment: Modified Supra-Aortic Frozen Elephant Trunk (SA-FET) Device
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Supra-Aortic Branch Vessel Stenting With a Hybrid Frozen Elephant Trunk Device: A Novel Wire-Reinforced Fenestration Technique
- Plain-language title
- Modified stent graft device for aortic arch surgery in aortic aneurysm or dissectionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 21 October 2026